Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Health plan trustees at a Minneapolis-based construction workers union are suing a subsidiary of UnitedHealth Group for ...

UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...

The findings showcased Zepbound's standout efficacy, with participants losing 50.3 lbs on average compared to 33.1 lbs with Wegovy. Additionally, nearly 32 percent of those taking Zepbound ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic, a medication that is approved by the FDA to treat Type 2 diabetes but is ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billion Danish kroner). Access and affordability have limited wider use of the drugs.